Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
-
Story Discovery
A legacy of blood cancer innovationBuilding on more than two decades of chronic myeloid leukemia research, the R&D teams at Novartis pursued an investigational treatment unlike any other.
-
Media ReleaseLatest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative diseaseAddition of Kisqali® (ribociclib) to endocrine therapy (ET) demonstrated a 28% risk reduction in invasive disease-free survival (iDFS) in subgroup of patients with node-negative (N0) disease at…
-
Media ReleaseNovartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CMLPhase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs.…
-
Media ReleaseNovartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticariaPatients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s…
-
Story People and Culture
A personal journey full circle, from curiosity about life on Earth to transformative therapies at Novartis -
Media ReleaseNovartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolioIn the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (…
-
Media ReleaseNovartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placeboSecondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical…
-
Media ReleaseNovartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cashNovartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the…
-
Media ReleaseNovartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHAPrimary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Press Program and the…
-
Pulse UpdateNovartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
-
Media ReleaseNovartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipelineTransaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancerMariana Oncology is a preclinical-stage biotechnology company focused…
-
Story People and Culture
From black holes to AI driven drug discovery – collaboration wins the dayDr Bülent Kızıltan, Global Head of AI & Computational Sciences
-
Media ReleaseLatest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative diseaseAddition of Kisqali® (ribociclib) to endocrine therapy (ET) demonstrated a 28% risk reduction in invasive disease-free survival (iDFS) in subgroup of patients with node-negative (N0) disease at…
-
Media ReleaseNovartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CMLPhase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs.…
-
Media ReleaseNovartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticariaPatients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s…
-
Media ReleaseNovartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolioIn the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (…
-
Media ReleaseNovartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placeboSecondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical…
-
Media ReleaseNovartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cashNovartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the…
-
Media ReleaseNovartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHAPrimary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Press Program and the…
-
Media ReleaseNovartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipelineTransaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancerMariana Oncology is a preclinical-stage biotechnology company focused…
-
Media ReleaseNovartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malariaThere is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic…
-
Media ReleaseNovartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumorsApproval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic…
-
Key ReleaseNovartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raisedAd hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including…
-
Media ReleaseNovartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosisContinuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis…
-
Key ReleaseNovartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raisedAd hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including…
-
Key ReleaseNovartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readoutsAd hoc announcement pursuant to Art. 53 LRFull year (continuing operations2)Net sales grew +10% (cc, +8% USD) with core operating income growing +18% (cc, +11% USD)Sales growth was mainly driven by…
-
Key ReleaseNovartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase IIIAnnonce événementielle au sens de l’art. 53 RCExercice complet (activités poursuivies2)Hausse de +10 % (tcc, +8 % USD) du chiffre d’affaires net et de +18 % (tcc, +11 % USD) du…
-
Key ReleaseStarkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-ErgebnissenAd-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr (fortzuführende Geschäftsbereiche2)Der Nettoumsatz wuchs um +10% (kWk, +8% USD), und das operative Kernergebnis verbesserte sich um +18% (…
-
Key ReleaseNovartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemiaMEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic…
-
Key ReleaseNovartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1;…
-
Key ReleaseNovartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNHAd hoc announcement pursuant to Art. 53 LR Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement…
-
Key ReleaseNovartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D DayAd hoc announcement pursuant to Art. 53 LR ‘Pure-play’ innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent…
-
Key ReleaseNovartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)Ad hoc announcement pursuant to Art. 53 LR Phase III ALIGN study met its primary endpoint, demonstrating superiority of atrasentan vs. placebo in proteinuria reduction at 36-week interim analysis1;…
-
Key ReleaseNovartis : hausse de 12% du chiffre d’affaires et de 21% du résultat opérationnel core (tcc¹). Spin-off de Sandoz, étapes importantes de l’innovation ; hausse des prévisions pour 2023Annonce événementielle au sens de l’art. 53 RC Le spin-off de Sandoz parachève la spécialisation d’Innovative Medicines dans les médicaments innovants le commentaire ci-dessous concerne les…
-
Key ReleaseNovartis steigert Umsatz um 12% und operatives Kernergebnis um 21% (fortzuführende Geschäftsbereiche, kWk¹). Sandoz abgespalten, wichtige Innovationsmeilensteine erreicht und Prognose 2023 erhöhtAd-hoc-Mitteilung gemäss Art. 53 KR Die Transformation zu einem Unternehmen, das rein auf innovative Medikamente spezialisiert ist, wurde mit dem Spin-off von Sandoz abgeschlossen; die…
-
Key ReleaseNovartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidanceAd hoc announcement pursuant to Art. 53 LR Transformation into a “pure-play” innovative medicines business is complete, with the spin-off of Sandoz; commentary below is on continuing…
-
Featured NewsNovartis Financial Results – Q1 2024Novartis announced the company’s financial results for the first quarter of 2024.
-
Featured NewsNovartis 2023 Financial ResultsNovartis announces the company’s fourth quarter and 2023 full year financial results.
-
Featured NewsJ.P. Morgan Healthcare Conference 2024
Latest news and interviews for media and investors
-
Featured NewsOur next eraNovartis poised to expand impact on human health as it begins next era.
-
Featured NewsNovartis Financial Results – Q3 2023 -
Featured NewsNovartis’ Giving & Volunteering wins ACCP’s 2023 Corporate Social Impact Team of the Year Award
-
Featured NewsNovartis Financial Results – Q2 2023Novartis announced the company’s financial results for the second quarter and first half of 2023.
-
Featured NewsNovartis Financial Results – Q1 2023Novartis announced the company’s financial results for the first quarter of 2023.
-
Featured NewsNovartis 2022 Financial ResultsNovartis announces the company’s fourth quarter and 2022 full year financial results.
-
Featured NewsWorld Economic Forum 2023 -
Featured NewsCreating positive social change through volunteeringOver 1 billion people volunteer worldwide, sharing their skills and experience, providing support within their communities, and offering emergency assistance to those in need. On International Volunteer Day (December 5), we join forces with the UN to recognize the tireless work of all volunteers and the contributions that they make.
-
Featured NewsNovartis Financial Results – Q3 2022
-
StatementViolence against innocent people runs counter to our work to improve human health
-
StatementNovartis condemns the terrorist actions against people in Israel and loss of innocent lives
-
StatementNovartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
-
StatementNovartis provides support for Moroccan earthquake victims
-
StatementGT005 (PPY988): Development Program in Geographic Atrophy
-
StatementNovartis statement on filing of Inflation Reduction Act lawsuit
-
StatementNovartis statement about Entresto® (sacubitril/valsartan) selection for Medicare Drug Price Negotiation Program
-
StatementEuropean Commission (EC) adopts decision endorsing CHMP recommendation to revoke the conditional marketing authorization for Adakveo® (crizanlizumab)
-
StatementCHMP recommends revoking the conditional marketing authorization for Adakveo® (crizanlizumab)
-
StatementNovartis unwavering in support one year on from the start of the war in Ukraine
On February 24, we marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while our unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.
-
StatementNovartis releases emergency funding of USD 1 million for people in Turkey and Syria, and launches employee donation and volunteering programs
-
StatementNovartis announces support for people affected by the earthquake in Turkey and Syria
-
Pulse UpdateNovartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
-
Pulse UpdateNovartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2
-
Pulse UpdateNovartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study
-
Pulse UpdateNovartis appoints Sloan Simpson as Global Head of Investor Relations
-
Pulse UpdateNovartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024
-
Pulse UpdateFDA approves Novartis Millburn facility for US commercial production of Pluvicto®
-
Pulse UpdateNovartis completes FDA filing for approval of Millburn facility to support Pluvicto® launch
-
Pulse UpdateNovartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023
-
Pulse UpdateNovartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease
-
Pulse UpdateFDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
-
Pulse UpdateNovartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
-
Pulse UpdateNovartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee
-
Story DiscoveryA legacy of blood cancer innovation
Building on more than two decades of chronic myeloid leukemia research, the R&D teams at Novartis pursued an investigational treatment unlike any other.
-
Story People and CultureA personal journey full circle, from curiosity about life on Earth to transformative therapies at Novartis
-
Story People and CultureFrom black holes to AI driven drug discovery – collaboration wins the day
Dr Bülent Kızıltan, Global Head of AI & Computational Sciences
-
Story From Our Labs
Drug delivery, service delivery, and the future of cancer careState-of-the-art Novartis manufacturing facility in Indianapolis fortifies the foundation of an entirely new paradigm in pharmaceutical drug delivery.
-
Story Patient Perspectives
Listening to the CML patient communityImproving the patient experience and removing potential barriers to clinical trial participation
-
Story People and Culture
How collaboration can enhance your science careerKumar Veerapen, Senior Expert I Data Science
-
Story Patient Perspectives
Giving voice to people with a misunderstood diseaseShanelle Gabriel was diagnosed with lupus — a chronic autoimmune disease that mostly affects women of African American and Hispanic descent — while she was at college. Today, as a singer, poet and advocate, she uses her voice to highlight challenges faced by people living with this complex and often misunderstood condition.
Photos: Brent Stirton, Getty Images for Novartis
-
Story Discovery
Water project revives rural community in IndiaNovartis is aiming for water neutrality in our own operations by 2030. In India, we are contributing to this goal through a project near Hyderabad with a nonprofit organization. By tackling both water scarcity and the deprivation it causes, the project has revived the community.
Photos: Bjoern Myhre, Novartis
-
Story Access to Healthcare
A partnership against epilepsyParts of Cameroon have rates of epilepsy that are among the highest in the world. Despite the availability of effective therapies, poverty, a lack of medical resources and superstition about the causes of epilepsy often lead to inadequate treatment and social exclusion for people living with the neurological condition. Novartis is working with a Catholic mission on the ground in a central part of the country to overcome these barriers and improve care.
Photos: Bjoern Myhre, Novartis
-
Story Patient Perspectives
Facing the fear of breast cancer recurrenceWhen Laurie Brunner found a lump in her breast just before Thanksgiving in 2018, it was the beginning of one of the most difficult periods of her life. Although treatment put her cancer into remission, she found herself dealing with an emotional toll that affects many survivors of early-stage breast cancer: the fear of it coming back.
Photos: Brent Stirton, Getty Images for Novartis
-
Story People and Culture
Balancing family life with a legal career -
Story Discovery
Innovation fueled by compassionWe're striving to help more people with chronic spontaneous urticaria—a skin condition marked by hives and distressful itching—return to their daily lives.
2024 ASCO Annual Meeting
Novartis attended the 2024 ASCO Annual Meeting from May 31 to June 4, 2024
Novartis in Society Integrated Report 2023
Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.
Annual Report 2023
This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also contains our operating and financial results, accompanied by audited annual financial statements.
Humanitarian response
Violence against innocent people runs counter to our work to improve human health
Novartis condemns all acts of terrorism and violence. Our thoughts are with all those affected by the tragic events that continue to unfold in Israel, Gaza and the West Bank.
Novartis unwavering in support one year on from the start of the war in Ukraine
On February 24, we marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while our unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.
#NovartisNews
Tweets from the Media Relations team
